Across TCGA pan-cancer cohorts, ZSCAN5B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZSCAN5B data layer compared with 26 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ZSCAN5B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZSCAN5B expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

BLCA, SARC, and PRAD are the cancer types where ZSCAN5B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.051	0.600	<.001	12	view →
SARC	DFS	Median	All	0.024	0.611	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	3	view →
STAD	OS	Median	IV	1.000	0.299	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ZSCAN5B tumor-vs-normal RNA expression · all ZSCAN5B data types